Profile
| Metric | Value |
|---|---|
| Full Name | Astria Therapeutics, Inc. |
| Ticker | NASDAQ: ATXS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | astriatx.com |
| Employees | 78 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $13.20 | |
| Price, 1D Change | +2.09% | |
| Market Cap | $754M | |
| - | ||
| PE Ratio | - | |
| Beta | 1.23 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$1.68 | |
| EPS, 1Y Change | +30.64% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:6 | |
| Next Split | N/A | N/A |
| Last Ticker Change | CATB | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.68 | |
| EPS Estimate | -$2.12 | |
| EPS Est. Change | -26.51% | |
| Revenue | $0.00 | |
| Revenue Estimate | $10.28M | |
| Revenue Est. Change | - | |
| Current Price | $13.20 | |
| Price Target | - | $13.00 |
| Price Tgt. Change | - | -1.52% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.28 | -$2.42 | -6.13% | |
| -$1.95 | -$1.68 | +13.93% | |
| -$2.12 | N/A | -26.51% | |
| -$2.36 | N/A | -40.46% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| $10.28M | N/A | - | |
| $3.50M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +52.25% | |
| Price, 3Y | -14.06% | |
| Market Cap, 1Y | +54.00% | |
| Market Cap, 3Y | +78.38% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | +30.64% | |
| EPS, 3Y | +93.17% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $13.20 | |
| SMA 200 | $7.93 | |
| SMA 200 vs Price | -39.93% | |
| SMA 50 | $12.72 | |
| SMA 50 vs Price | -3.67% | |
| Beta | 1.23 | |
| ATR | $0.22 | |
| 14-Day RSI | 64.39 | |
| 10-Day Volatility | 15.34% | |
| 1-Year Volatility | 74.10% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$1.68 | |
| Gross Profit | $0.00 | |
| Gross Margin | - | |
| Operating Profit | -$111.56M | |
| Operating Margin | - | |
| Net Income | -$94.26M | |
| Net Margin | - | |
| EBITDA | -$111.56M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| 17.49 | ||
| 17.49 | ||
| - | ||
| - | ||
| 16.84 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 1,067.31 | ||
| 5.46 | ||
| -3.88 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $223.94M | |
| $328.13M | ||
| $342.36M | ||
| $334.64M | ||
| $23.10M | ||
| $19.13M | ||
| Total Debt | $5.35M | |
| $1.38M | ||
| $4.32M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $94.26M | ||
| $111.56M | ||
| $0.00 | ||
| $0.00 | ||
| - | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$81.21M | ||
| -$191.86M | ||
| $157.20M | ||
| Capex | $325.00K | |
| -$81.54M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Cantor Fitzgerald | → | |
| HC Wainwright & Co. | → | |
| Wedbush | → | |
| JMP Securities | → | |
| Jefferies | → | |
| HC Wainwright & Co. | → | |
| Cantor Fitzgerald | → | |
| JMP Securities | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with ATXS
Data Sources & References
- ATXS Official Website www.astriatx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1454789/000110465925110377/0001104659-25-110377-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1454789/000141057825000309/0001410578-25-000309-index.htm
- ATXS Profile on Yahoo Finance finance.yahoo.com/quote/ATXS
- ATXS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/atxs
FAQ
What is the ticker symbol for Astria Therapeutics, Inc.?
The ticker symbol for Astria Therapeutics, Inc. is NASDAQ:ATXS
Does Astria Therapeutics, Inc. pay dividends?
No, Astria Therapeutics, Inc. does not pay dividends
What sector is Astria Therapeutics, Inc. in?
Astria Therapeutics, Inc. is in the Healthcare sector
What industry is Astria Therapeutics, Inc. in?
Astria Therapeutics, Inc. is in the Biotechnology industry
What country is Astria Therapeutics, Inc. based in?
Astria Therapeutics, Inc. is headquartered in United States
When did Astria Therapeutics, Inc. go public?
Astria Therapeutics, Inc. initial public offering (IPO) was on June 25, 2015
Is Astria Therapeutics, Inc. in the S&P 500?
No, Astria Therapeutics, Inc. is not included in the S&P 500 index
Is Astria Therapeutics, Inc. in the NASDAQ 100?
No, Astria Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Astria Therapeutics, Inc. in the Dow Jones?
No, Astria Therapeutics, Inc. is not included in the Dow Jones index
When was Astria Therapeutics, Inc. last earnings report?
Astria Therapeutics, Inc.'s most recent earnings report was on November 12, 2025
When does Astria Therapeutics, Inc. report earnings?
The next expected earnings date for Astria Therapeutics, Inc. is March 18, 2026